Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant PK and Bioavailability Study
NCT05061563Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elinzanetant in vasomotor symptoms (2 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve from zero to infinity, Maximum observed drug concentration and 2 more. Started Sep 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05061563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061563.